Fintel reports that on September 25, 2024, Macquarie initiated coverage of Core Scientific, Inc. - Equity Right (OTCPK:CORZR) with a Outperform recommendation.
Analyst Price Forecast Suggests 27.63% Upside
As of August 6, 2024, the average one-year price target for Core Scientific, Inc. - Equity Right is $0.41/share. The forecasts range from a low of $0.32 to a high of $0.52. The average price target represents an increase of 27.63% from its latest reported closing price of $0.32 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Core Scientific, Inc. - Equity Right is 614MM. The projected annual non-GAAP EPS is -0.01.
What is the Fund Sentiment?
There are 2 funds or institutions reporting positions in Core Scientific, Inc. - Equity Right. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to CORZR is 0.02%, an increase of 87.76%. Total shares owned by institutions decreased in the last three months by 70.87% to 1,010K shares.
What are Other Shareholders Doing?
BlackRock Credit Strategies Fund holds 952K shares.
MAI Capital Management holds 57K shares. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
